Loading....
The RPGRIP1 Project
to prevent vision loss
The Path Toward Treatment
Odylia Therapeutics is a nonprofit (501c3) biotech focused on accelerating the development of treatments for people with rare diseases. Odylia is developing a gene therapy to treat vision loss caused by RPGRIP1 mutations. Currently, Odylia is conducting late-stage preclinical experiments and preparing for clinical trials. In November of 2021, the FDA granted Orphan Drug and Rare Pediatric Drug designations to the RPGRIP1 program. This means the FDA recognizes the maturity of this program and the importance of continuing to move toward clinical trials. We believe these designations will provide significant benefits throughout the development process as we move the treatment forward for patients.
The next step is to manufacture the high-quality gene therapy materials (vector, capsid, etc). These materials will be used in the final toxicology study AND will also be used in the clinical trials. The treatment can’t move forward without them.
How Can YOU Help?
There are multiple ways you can support the RPGRIP1 Project.
- Consider making a donation below. Funds will be used to manufacture the gene therapy and to conduct critical toxicology studies. Without philanthropic support, this promising treatment may stall.
- Set up a personal fundraising page and ask your network to contribute. You can find directions HERE.
- Raise awareness! If you know others who may be interested in the RPGRIP1 Program, encourage them to sign up for our email list HERE to receive periodic updates about the program.
Thank You!
Working together, we can develop treatments to prevent vision loss. We are so grateful for your support and look forward to sharing our success story!
We would LOVE it if you could let your friends and loved ones know about
your support of our work by sharing this via social media using the links below!